IMNN vs. MNPR, TNXP, BNTC, AGE, NNVC, ABVC, EDSA, MIRA, ERNA, and RDHL
Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Monopar Therapeutics (MNPR), Tonix Pharmaceuticals (TNXP), Benitec Biopharma (BNTC), AgeX Therapeutics (AGE), NanoViricides (NNVC), ABVC BioPharma (ABVC), Edesa Biotech (EDSA), MIRA Pharmaceuticals (MIRA), Eterna Therapeutics (ERNA), and RedHill Biopharma (RDHL). These companies are all part of the "pharmaceutical preparations" industry.
Monopar Therapeutics (NASDAQ:MNPR) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 41.6% of Monopar Therapeutics shares are owned by insiders. Comparatively, 3.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Monopar Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 203.86%. Imunon has a consensus price target of $13.00, indicating a potential upside of 802.78%. Given Monopar Therapeutics' higher possible upside, analysts plainly believe Imunon is more favorable than Monopar Therapeutics.
Monopar Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
In the previous week, Imunon had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Monopar Therapeutics. Imunon's average media sentiment score of 0.00 equaled Monopar Therapeutics'average media sentiment score.
Monopar Therapeutics received 30 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 70.37% of users gave Monopar Therapeutics an outperform vote.
Monopar Therapeutics has higher earnings, but lower revenue than Imunon. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Monopar Therapeutics' return on equity of -98.04% beat Imunon's return on equity.
Summary
Imunon beats Monopar Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Imunon News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
